atyr
pharma
announces
partner
kyorin
pharmaceutical
doses
first
subjects
phase
trial
japan
san
diego
globe
newswire
atyr
pharma
nasdaq
life
biotherapeutics
company
engaged
discovery
development
innovative
medicines
based
novel
biological
pathways
today
announced
partner
kyorin
pharmaceutical
kyorin
wholly
owned
subsidiary
kyorin
holdings
dosed
first
subjects
phase
trial
atyr
lead
therapeutic
candidate
known
japan
phase
trial
conducted
kyorin
study
evaluate
safety
pharmacokinetics
immunogenicity
healthy
japanese
male
volunteers
assuming
successful
completion
study
kyorin
would
able
initiate
patient
trials
interstitial
lung
diseases
ilds
japan
potential
immunomodulator
may
present
promising
new
approach
treating
ilds
said
sanjay
shukla
president
chief
executive
officer
atyr
date
favorable
safety
profile
trials
conducted
australia
look
forward
outcome
study
japanese
population
continue
advance
ild
program
pleased
initiate
clinical
development
japan
dosing
first
healthy
volunteers
study
said
yutaka
ogihara
president
chief
executive
officer
kyorin
holdings
trial
important
step
towards
offering
potential
new
treatment
ild
patients
kyorin
atyr
partner
development
commercialization
ilds
japan
per
agreement
atyr
previously
received
million
upfront
payment
eligible
receive
million
aggregate
upon
achievement
certain
development
regulatory
sales
milestones
well
tiered
royalties
net
sales
japan
kyorin
exclusive
rights
commercialize
japan
ilds
atyr
developing
potential
therapeutic
patients
inflammatory
lung
diseases
fusion
protein
comprised
domain
histidyl
trna
synthetase
fused
fc
region
human
antibody
selective
modulator
downregulates
innate
adaptive
immune
response
inflammatory
disease
states
atyr
currently
enrolling
phase
trial
evaluating
patients
pulmonary
sarcoidosis
form
interstitial
lung
disease
phase
study
dose
study
designed
evaluate
safety
tolerability
steroid
sparing
effect
immunogenicity
pharmacokinetics
profile
multiple
doses
response
pandemic
atyr
recently
initiated
phase
clinical
trial
patients
severe
respiratory
complications
phase
study
randomized
double
blind
study
designed
evaluate
safety
preliminary
efficacy
single
dose
atyr
atyr
biotherapeutics
company
engaged
discovery
development
innovative
medicines
based
novel
biological
pathways
atyr
research
development
efforts
concentrated
newly
discovered
area
biology
extracellular
functionality
signaling
pathways
trna
synthetases
atyr
built
global
intellectual
property
estate
directed
potential
pipeline
protein
compositions
derived
trna
synthetase
genes
extracellular
targets
atyr
primary
focus
product
candidate
binds
receptor
designed
immune
engagement
inflammatory
lung
diseases
information
please
visit
http
kyorin
trusted
among
patients
professionals
medical
industry
kyorin
pharmaceutical
strives
company
contributes
public
health
recognized
one
social
significance
improving
presence
specific
therapeutic
areas
global
discovery
novel
drugs
kyorin
pharmaceutical
uses
franchise
customer
strategy
marketing
efforts
focused
respiratory
otolaryngology
urology
drug
discovery
deploying
concentration
promoting
activities
aimed
drug
discovery
actively
searching
introducing
external
drug
discovery
themes
well
program
development
information
please
visit
http
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
usually
identified
use
words
anticipates
believes
estimates
expects
intends
may
plans
projects
seeks
variations
words
similar
expressions
intend
statements
covered
safe
harbor
provisions
statements
making
statement
purposes
complying
safe
harbor
provisions
statements
include
statements
regarding
potential
therapeutic
benefits
applications
timelines
plans
respect
certain
development
activities
scope
timelines
clinical
trials
potential
benefits
collaborations
certain
development
goals
statements
also
reflect
current
views
plans
intentions
expectations
strategies
prospects
based
information
currently
available
us
assumptions
made
although
believe
plans
intentions
expectations
strategies
prospects
reflected
suggested
statements
reasonable
give
assurance
plans
intentions
expectations
strategies
attained
achieved
statements
based
estimates
assumptions
management
although
believe
reasonable
inherently
uncertain
furthermore
actual
results
may
differ
materially
described
statements
affected
variety
risks
factors
beyond
control
including
without
limitation
uncertainty
regarding
pandemic
risks
associated
discovery
development
regulation
product
candidates
risk
partners
may
cease
delay
preclinical
clinical
development
activities
existing
future
product
candidates
variety
reasons
including
difficulties
delays
patient
enrollment
planned
clinical
trials
possibility
existing
collaborations
could
terminated
early
risk
may
able
raise
additional
funding
required
business
product
development
plans
well
risks
set
forth
recent
annual
report
form
quarterly
reports
form
sec
filings
except
required
law
assume
obligation
update
publicly
statements
whether
result
new
information
future
events
otherwise
contact
ashlee
dunston
investor
relations
corporate
communications
adunston
